Search research articles
Contact Us
Filters
Showing results (191-200 of 388) with videos related to
Page
of 39
Sort By:
Oncology Reports
|
March 10, 2005
Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients
Camillo Porta, Ilaria Imarisio, Mara De Amici, et al.
The Lancet. Oncology
|
December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Brian I Rini, Sumanta K Pal, Bernard J Escudier, et al.
Clinical Genitourinary Cancer
|
September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer
Zeynep B Zengin, Sumanta K Pal, David F McDermott, et al.
Critical Reviews in Oncology/Hematology
|
November 8, 2019
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers
Eleonora Rofi, Marzia Del Re, Elena Arrigoni, et al.
Critical Reviews in Oncology/Hematology
|
April 29, 2020
Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers
Eleonora Rofi, Marzia Del Re, Elena Arrigoni, et al.
Journal of Translational Medicine
|
December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
Tomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Targeted Oncology
|
October 3, 2015
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
Roberto Iacovelli, Franco Nolè, Elena Verri, et al.
Japanese Journal of Clinical Oncology
|
November 19, 2020
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study
Alessandra Mosca, Ugo De Giorgi, Giuseppe Procopio, et al.
The Oncologist
|
September 23, 2022
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
Toni K Choueiri, Camillo Porta, Cristina Suárez, et al.
Oncology
|
September 28, 2021
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
Umberto Basso, Giuseppe Procopio, Giuseppe Fornarini, et al.
Page
of 39
Search research articles
Search
Showing results (191-200 of 388) with videos related to
Sort By:
Page
of 39
Oncology Reports
|
March 10, 2005
Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients
Camillo Porta, Ilaria Imarisio, Mara De Amici, et al.
The Lancet. Oncology
|
December 8, 2019
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
Brian I Rini, Sumanta K Pal, Bernard J Escudier, et al.
Clinical Genitourinary Cancer
|
September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer
Zeynep B Zengin, Sumanta K Pal, David F McDermott, et al.
Critical Reviews in Oncology/Hematology
|
November 8, 2019
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers
Eleonora Rofi, Marzia Del Re, Elena Arrigoni, et al.
Critical Reviews in Oncology/Hematology
|
April 29, 2020
Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers
Eleonora Rofi, Marzia Del Re, Elena Arrigoni, et al.
Journal of Translational Medicine
|
December 13, 2022
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
Tomer Meirson, Valerio Nardone, Francesca Pentimalli, et al.
Targeted Oncology
|
October 3, 2015
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis
Roberto Iacovelli, Franco Nolè, Elena Verri, et al.
Japanese Journal of Clinical Oncology
|
November 19, 2020
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study
Alessandra Mosca, Ugo De Giorgi, Giuseppe Procopio, et al.
The Oncologist
|
September 23, 2022
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
Toni K Choueiri, Camillo Porta, Cristina Suárez, et al.
Oncology
|
September 28, 2021
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16)
Umberto Basso, Giuseppe Procopio, Giuseppe Fornarini, et al.
Page
of 39